Abstract
The prognosis of chronic myeloid leukaemia (CML) has improved remarkably over the last 11 years with the introduction of tyrosine kinase inhibitors (TKIs) in clinical practice. Here we intend to focus on clinically based problems and their solution based on the evidence from literature and our experience as a centre for excellence. Recent results from trials with first and second generation TKIs have help to clarify some, but not all, of the common clinical dilemmas that physicians face when treating CML patients. CML treatment received a paradigm shift with the launch of TKIs. However, questions remain about adherence, tolerability, toxicity, resistance, and management and about the selection of second-generation drugs and the interpretion of responses and the role of stem cell transplantation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
